

Amgen partners with LifeMax Laboratories in the formation of AmMaxBio, Inc.

Client News

April 16, 2020

Gunderson Dettmer represented Amgen in connection with the launch of AmMax Bio, in partnership with LifeMax Laboratories. In the transaction, Amgen provided to AmMax an exclusive worldwide license for the right to develop, manufacture and commercialize AMG 820, a monoclonal antibody against the colony-stimulating factor 1 receptor (“CSF-1R”) that has completed Phase I/II clinical studies in solid tumors. AmMax Bio will focus on treating orphan diseases.

The Gunderson deal team was led by partners Kirt Shuldberg and Brendan McCarthy and included Colin Chapman, Brittany Nicely and Richard Sapien.

In an [announcement](#) of the deal Larry Hsu, LifeMax and AmMax CEO said, “The licensing of AMG 820 fits very well with our focus on developing first-in-class or best-in-class therapies for orphan diseases with significant unmet needs. We look forward to bringing this much needed therapy to people with TGCT and other orphan diseases that involve CSF-1/CSF-1R biology.”

Related People

Kirt W Shuldberg

PARTNER

P +1 858 436 8060

Brendan C. McCarthy

PARTNER

P +1 858 436 8013

Colin D. Chapman

PARTNER

P +1 650 463 5490

Brittany M. Nicely

ASSOCIATE

P +1 858 436 8067

Featured Insights

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act

INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad

INSIGHTS

Tech Brew Interviews Aaron Rubin in “Where the legal battle stands around copyright and AI training”

CLIENT NEWS

Latin America Fintech Belvo Announces \$15M Funding

INSIGHTS

Legal 500 Country Comparative Guides 2025: Venture Capital (Singapore)